Skip to content
Screener

Journey Medical Corporation DERM Q1 2025 earnings

Reported May 14, 2025 · After market close

Revenue$13.1MMiss by $1.8M
EPS-$0.18Beat by $0.06
Revenue estimate$14.9M
EPS estimate-$0.24

Next report

Nov 11, 2026 (in 2 months)
Revenue estimate$21.9M
EPS estimate$0.02

Financials

Q1 2025

Income statement

See full
Revenue$13.1M+0.8%
Gross profit$8.3M+34.4%
Operating income-$3.3M+67.1%
Net income-$4.1M+61.0%
EPS (diluted)-$0.18+66.0%

Balance sheet

See full
Cash & equivalents$21.1M-12.4%
Total debt$25.2M+70.4%
Total equity$21.5M+66.3%
Total assets$85.0M+27.6%

Cash flow

See full
Operating cash flow-$2.8M+43.6%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$136.32M+91.7%
Enterprise value$140.41M+127%
P/S2.4×+1.5×

Profitability

See full
Gross margin66.5%-4.4pp

Returns & leverage

See full
Debt / equity1.2×0.0×
Current ratio1.3×+0.1×

Segments

By product

See full
Qbrexza$5.2M+2.9%
Accutane$3.7M-37.2%
Emrosi$2.1M—
Other Legacy$727.0K-37.7%

By segment

See full
Dermatological$13.1M-6.4%

FAQ

When did Journey Medical Corporation report Q1 2025 earnings?
Journey Medical Corporation (DERM) reported Q1 2025 earnings on May 14, 2025 after market close.
What were Journey Medical Corporation's Q1 2025 revenue and EPS?
Journey Medical Corporation reported revenue of $13.1M and eps of $-0.18 for Q1 2025.
Did Journey Medical Corporation beat estimates in Q1 2025?
Revenue missed the consensus estimate of $14.9M by $1.8M. EPS beat the consensus estimate of $-0.24 by $0.06.
How did Journey Medical Corporation's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 0.8% from $13.0M a year earlier and eps grew 66.0% from $-0.53.
Where can I find Journey Medical Corporation's Q1 2025 SEC filings?
You can read the 8-K earnings release (0001104659-25-048502) and the 10-Q periodic report (0001410578-25-001296) directly on SEC EDGAR. The filing index links above go to sec.gov.